L-BASE
Biomedical
Project
New drug development for overcoming of EGFR-targeting anticancer drug resistance
Project Summary
L-BASE has discovered new target, CAGE in 2002. This target is related to EGFR resistance mechanism.
L-BASE has patented peptides which control CAGE function. LB102 is one of them and shows good efficacy against EGFR mutation especially T790M mutation.
L-BASE has patented peptides which control CAGE function. LB102 is one of them and shows good efficacy against EGFR mutation especially T790M mutation.
Business Model
Bio Venture - New Drug Development
Main Achievements
L-BASE has published 13 international papers.
And filed several PCT patents.
And filed several PCT patents.
Date of Establishment2015-11-11
AcceleratorActnerLab
StageBiomedical
Date of TIPS Selection2016-11-01